Hematologic Manifestations of Liver Disease

Seminars in Hematology

Volumn 50, Issue 3, 2013, Pages 216-221

  Marks, Peter W ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIVIRUS AGENT; BOCEPREVIR; DABIGATRAN; DESMOPRESSIN; FONDAPARINUX; FRESH FROZEN PLASMA; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIBAVIRIN; RIVAROXABAN; TELAPREVIR; THROMBOPOIETIN; TRANEXAMIC ACID; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CYTOPENIA; DISEASE ASSOCIATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEMOSTASIS; HEPATITIS C; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LUNG EMBOLISM; NEUTROPHIL COUNT; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS; THROMBOSIS PREVENTION; VARICOSIS;

ANEMIA; BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; LEUKOPENIA; LIVER DISEASES; THROMBOCYTOPENIA;

EID: 84881589052     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.06.003     Document Type: Article

References (50)

1. Brummel-Ziedins K, Mann KG. Molecular basis of blood coagulation. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al, editors. Hematology: basic principles and practice. Ed 6. Philadelphia. Sanders: Elsevier, 2013:1821-41.
2. Muszbek L., Bereczky Z., Bagoly Z., et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011, 91:931-972.
3. Furie B., Furie B.C. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990, 75:1753-1762.
4. Martinez J., MacDonald K.A., Palascak J.E. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983, 61:1196-1202.
5. Kuter D.J. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010, 47:243-248.
6. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112:219-230.
7. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341:1986-1995.
8. Stein S.F., Harker L.A. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982, 9:217-230.
9. Rauff B., Idrees M., Shah S.A., et al. Hepatitis associated aplastic anemia: a review. Virol J 2011, 8:87.
10. Stasi R., Willis F., Shannon M.S., Gordon-Smith E.C. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009, 23:1275-1297.
11. Qamar A.A., Grace N.D., Groszmann R.J., et al. Incidence, prevalence, and clinical significance of abnormal hematologic indicies in compensated cirrhosis. Clin Gastroenterol Hepatol 2009, 7:689-695.
12. Gonzalez-Casas R., Jones E.A., Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol 2009, 15:4653-4658.
13. Morse E.E. Mechanisms of hemolysis in liver disease. Ann Clin Lab Sci 1990, 20:169-174.
14. Chitale A.A., Sterling R.K., Post A.B., et al. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 1998, 65:993-995.
15. Casey L.C., Lee W.M. Hepatitis C therapy update. Curr Opin Gastroenterol 2012, 28:188-192.
16. Sulkowski M.S., Poordad F., Manns M.P., et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: Analysis from the sprint-2 trial. Hepatology 2013, 57:974-984.
17. Fielder P.J., Gurney A.L., Stefanich E., et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996, 87:2154-2161.
18. Martin T.G., Somberg K.A., Meng Y.G., et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997, 127:127-131.
19. Afdhal N.H., Giannini E.G., Tayyab G., et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012, 367:716-724.
20. Pluta A., Gutkowski K., Hartleb M. Coagulopathy in liver diseases. Adv Med Sci 2010, 55:16-21.
21. Sibulesky L., Nguyen J.H., Paz-Fumagalli R., et al. Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C. World J Gastroenterol 2009, 15:5010-5013.
22. Tandon P., Doucette K., Fassbender K., et al. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. J Viral Hepat 2011, 18:e381-e393.
23. Sheehan V., Weir A., Waters B. Severe neutropenia in patients with chronic hepatitis C: a benign condition 2012, 129:96-100.
24. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365:147-156.
25. Tripodi A., Anstee Q.M., Sogaard K.K., et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011, 9:1713-1723.
26. Tripodi A., Caldwell S.H., Hoffman M., et al. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007, 26:141-148.
27. Watala C., Golanski J., Kardas P. Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb J 2003, 1:7.
28. Porte R.J., Lisman T., Tripodi A., et al. The international normalized ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010, 10:1349-1353.
29. Segal J.B., Dzik W.H. Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive diagnostic procedures: an evidence-based review. Transfusion 2005, 45:1413-1425.
30. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004, 126:11-28.
31. Mumtaz H., Williams V., Hauer-Jensen M., et al. Central venous catheter placement in patients with disorders of hemostasis. Am J Surg 2001, 180:503-506.
32. Perdigão J.P., de Almeida P.C., Rocha T.D., et al. Postoperative bleeding after dental extraction in liver pretransplant patients. J Oral Maxillofac Surg 2012, 70:e177-e184.
33. Roberts L.N., Patel R.K., Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010, 148:507-521.
34. Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thromb Res 2012, 130:1-6.
35. Wang S.C., Shieh J.F., Chang K.Y., et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010, 42:2590-2593.
36. Senzolo M., Sartori M.T., Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?. HPB (Oxford) 2009, 11:459-464.
37. Huard G., Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. Int J Hepatol 2012, Epub 2012 Jun 20.
38. Macnicholas R., Olliff S., Elias E., Tripathi D. An update on the diagnosis and management of Budd-Chiari syndrome. Expert Rev Gastroenterol Hepatol 2012, 6:731-744.
39. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
40. Stanworth S.J., Brunskill S.J., Hyde C.J., et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004, 126:139-152.
41. Youssef W.I., Salazar F., Dasarathy S., et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003, 98:1931-1934.
42. Patanwala A. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011, 45:990-999.
43. Krisl J.C., Meadows H.E., Greenberg C.S., Mazur J.E. Clinical usefulness of recombinant factor VII in patients with liver failure undergoing invasive procedures. Ann Pharmacother 2011, 45:1433-1438.
44. Yank V., Tuohy C.V., Logan A.C., et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011, 154:529-540.
45. Mannucci PM, Franchini M. Recombinant factor VIIa as haemostatic therapy in advanced liver disease. Blood Transfus. 2012; Oct 10:1-5. [Epub ahead of print].
46. Gluud L.L., Klingenberg S.L., Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012, 18:1.
47. Boylan J.F., Klinck J.R., Sandler A.N., et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996, 85:1043-1048.
48. Gunawan B., Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006, 23:115-120.
49. Cattaneo N., Tenconi P.M., Alberca I., et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990, 64:358-360.
50. de Franchis R., Arcidiacono P.G., Carpinelli L., et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993, 18:1102-1107.